TL;DR
A randomized U.S. trial compared patient-controlled digital disclosure of APOE genetic results with disclosure by a genetic counselor over telehealth. The digital approach met the study’s noninferiority criteria for knowledge, anxiety and disease-specific distress among selected participants; the supplied report does not include the numerical results or establish safety for every patient.
A U.S. randomized trial reported that a patient-controlled digital platform for disclosing Alzheimer’s-related genetic test results met predefined noninferiority criteria compared with a genetic counselor’s telehealth disclosure, as measured by participants’ knowledge, anxiety and disease-specific distress. The study, published in JAMA Neurology, examined how selected adults aged 60 to 80 responded to receiving sensitive results online rather than first discussing them with a clinician.
Get everyday helpers delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The eSMARTER trial randomized participants in a 2-to-1 ratio to digital or clinician-mediated disclosure of their apolipoprotein E, or APOE, genotype. The online option included a secure website and an SMS-based chat, with educational material and optional personalized estimates of the risk of mild cognitive impairment or dementia by age 85. Participants could request clinician assistance before or after disclosure, or choose it instead of the digital method.
Of 13,033 GeneMatch members invited, 666 were randomized and 651 received APOE results and entered the primary analyses: 435 in the digital group and 216 in the telehealth group. Participants had an average age of 68; 67% were women. The researchers measured knowledge, anxiety and disease-specific distress at several points through six months after APOE disclosure.
Six months later, participants could opt into testing for plasma phosphorylated tau 217 (p-tau217), a blood biomarker associated with Alzheimer’s disease pathology. Results were categorized as negative, intermediate or positive and disclosed using the participant’s assigned method. The supplied report describes this comparison as secondary; it does not provide numerical findings for the p-tau217 outcomes.
Online Results and Patient Support
The findings address a practical issue as test results become available through patient portals: people may see genetic or biomarker information before speaking with a health professional. In the United States, the 21st Century Cures Act generally requires medical test results to be made available to patients without delay. A structured digital process could offer education and a route to clinician help when specialist time is limited.
The result is not a blanket endorsement of unsupervised disclosure. Noninferiority means the digital method did not perform worse than the comparison method beyond a predefined statistical margin on the trial’s selected outcomes. It does not show that every participant preferred online results, that the approaches are identical, or that the platform is appropriate for every clinical situation. Nor does it establish that a test predicts an individual’s future with certainty.
The question has added relevance as anti-amyloid medicines such as lecanemab and donanemab are used in treatment decisions. Genetic and blood-based information may inform discussions about risk and assessment, but results need interpretation alongside a person’s health and circumstances. The trial measured disclosure outcomes, not whether digital delivery improves treatment choices or health outcomes.
Products Worth Considering

Sonos Five Wireless HiFi Speaker, Black

LG 27GR83Q-B 27-inch Ultragear QHD IPS Gaming Monitor

Logitech MX Keys S Combo Wireless Keyboard and Mouse, Graphite
As an affiliate, we earn on qualifying purchases.
How the eSMARTER Trial Worked
The fully remote trial recruited participants through GeneMatch from October 2024 to February 2025, with follow-up completed in November 2025. Eligible volunteers were 60 to 80, had previously taken an APOE test without receiving the result, had internet access, spoke English and agreed to provide blood samples. Researchers excluded people with elevated depressive symptoms, indicators of suicidality, untreated or unstable major psychiatric illness, or communication difficulties.
The sample was not broadly representative of all older adults: 90% were White, 78% had at least a college education and 52% lived in rural areas. Two-thirds reported a family history of Alzheimer’s disease. The results therefore speak most directly to people who met the study criteria and were willing and able to take part in a remote research trial, rather than to all patients offered testing in routine care.
APOE status can indicate genetic susceptibility, while p-tau217 is a blood-based marker linked to disease pathology. Neither should be presented as a standalone diagnosis of a person’s future condition. The researchers used a research-use-only assay for p-tau217, a detail that limits assumptions about how those results compare with tests used in ordinary clinical practice.
“The study tested whether digital APOE result disclosure was noninferior to clinician-mediated telehealth disclosure for knowledge, anxiety and disease-specific distress.”
— The eSMARTER researchers, as described in the supplied report
Limits of the Available Evidence
The source material states that digital APOE disclosure met the trial’s primary objectives, but the excerpt ends before giving the numerical outcome data, confidence intervals or the noninferiority margins. It is not possible from the supplied information to quantify how much scores changed or how close the group differences were to the study thresholds.
The excerpt also does not report the detailed results after p-tau217 disclosure, including participant numbers, group comparisons or any adverse effects. Although the trial assessed anxiety and distress, the available account does not describe individual experiences or whether some participants chose clinician support. Wider applicability remains uncertain because the study excluded people with certain mental health concerns and communication difficulties and enrolled a largely White, relatively highly educated sample.
Evidence Needed for Wider Use
The next step is closer examination of the full trial results, including effect estimates, statistical margins, participant use of optional clinician support and findings from the secondary p-tau217 comparison. Further studies would need to test digital disclosure with more diverse patient groups, across different health systems and with results returned as part of routine care.
For now, the trial offers evidence about measured responses to online APOE disclosure in a specific research population. It does not determine how any individual should receive a result or make treatment decisions. People considering genetic or biomarker testing can ask their clinician what a result can and cannot show, how it will be communicated and what support is available afterward.
Key Questions
What did the trial compare?
It compared patient-controlled digital disclosure of APOE genotype results with disclosure by a genetic counselor through telehealth. It also offered a later, optional p-tau217 blood test, but those results were a secondary comparison.
Did the study find online disclosure was as good as speaking with a clinician?
The researchers reported that digital APOE disclosure met predefined noninferiority criteria for knowledge, anxiety and disease-specific distress. That does not mean the methods were identical or that online disclosure is suitable for every patient.
Does an APOE result tell someone whether they will develop Alzheimer’s?
No. APOE genotype provides information about genetic susceptibility; it does not establish that a person will or will not develop Alzheimer’s disease. Individual results require careful interpretation.
What remains unknown about the findings?
The supplied report does not include the numerical results or detailed p-tau217 findings. It also does not establish how well the approach works for people outside the study’s selected, largely White and relatively highly educated sample.
Source: news-medical.net
